165 related articles for article (PubMed ID: 34420143)
21. Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial.
Basch E; Pugh SL; Dueck AC; Mitchell SA; Berk L; Fogh S; Rogak LJ; Gatewood M; Reeve BB; Mendoza TR; O'Mara AM; Denicoff AM; Minasian LM; Bennett AV; Setser A; Schrag D; Roof K; Moore JK; Gergel T; Stephans K; Rimner A; DeNittis A; Bruner DW
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):409-418. PubMed ID: 28463161
[TBL] [Abstract][Full Text] [Related]
22. Cognitive Interview-Based Validation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Adolescents with Cancer.
Reeve BB; McFatrich M; Pinheiro LC; Freyer DR; Basch EM; Baker JN; Withycombe JS; Sung L; Mack JW; Waldron MK; Mowbray C; Palma D; Hinds PS
J Pain Symptom Manage; 2017 Apr; 53(4):759-766. PubMed ID: 28062347
[TBL] [Abstract][Full Text] [Related]
23. Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®).
Caminiti C; Bryce J; Riva S; Ng D; Diodati F; Iezzi E; Sparavigna L; Novello S; Porta C; Del Mastro L; Procopio G; Cinieri S; Falzetta A; Calabrò F; Lorusso V; Cogoni AA; Tortora G; Maruzzo M; Passalacqua R; Cognetti F; Adamo V; Capelletto E; Ferrari A; Bagnalasta M; Bassi M; Nicelli A; De Persis D; D'Acunti A; Iannelli Patient E; Perrone F; Mitchell SA
Tumori; 2023 Jun; 109(3):324-334. PubMed ID: 35674125
[TBL] [Abstract][Full Text] [Related]
24. Linguistic Validation of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Korean.
Cho J; Yoon J; Kim Y; Oh D; Kim SJ; Ahn J; Suh GY; Nam SJ; Mitchell SA
J Glob Oncol; 2019 Mar; 5():1-10. PubMed ID: 30917069
[TBL] [Abstract][Full Text] [Related]
25. Use of patient-reported outcomes (PRO) data to complement exposure-response analysis in early clinical cancer drug development.
Xia H; Booth BP; Wang Y; Fan C; Bhatnagar V; Kluetz P; Fourie Zirkelbach J
J Patient Rep Outcomes; 2023 Nov; 7(1):116. PubMed ID: 37975967
[TBL] [Abstract][Full Text] [Related]
26. A multi-method approach to selecting PRO-CTCAE symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy.
Christiansen MG; Pappot H; Jensen PT; Mirza MR; Jarden M; Piil K
J Patient Rep Outcomes; 2023 Jul; 7(1):72. PubMed ID: 37462855
[TBL] [Abstract][Full Text] [Related]
27. Validity and reliability of the simplified Chinese patient-reported outcomes version of the common terminology criteria for adverse events.
Yang SS; Chen L; Liu Y; Lu HJ; Huang BJ; Lin AH; Sun Y; Ma J; Xie FY; Mao YP
BMC Cancer; 2021 Jul; 21(1):860. PubMed ID: 34315423
[TBL] [Abstract][Full Text] [Related]
28. Linking the European Organisation for Research and Treatment of Cancer Item Library to the Common Terminology Criteria for Adverse Events.
Gilbert A; Piccinin C; Velikova G; Groenvold M; Kuliś D; Blazeby JM; Bottomley A
J Clin Oncol; 2022 Nov; 40(32):3770-3780. PubMed ID: 35973158
[TBL] [Abstract][Full Text] [Related]
29. Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative.
Reeve BB; McFatrich M; Pinheiro LC; Weaver MS; Sung L; Withycombe JS; Baker JN; Mack JW; Waldron MK; Gibson D; Tomlinson D; Freyer DR; Mowbray C; Jacobs S; Palma D; Martens CE; Gold SH; Jackson KD; Hinds PS
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27650708
[TBL] [Abstract][Full Text] [Related]
30. Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Bruner DW; Hanisch LJ; Reeve BB; Trotti AM; Schrag D; Sit L; Mendoza TR; Minasian L; O'Mara A; Denicoff AM; Rowland JH; Montello M; Geoghegan C; Abernethy AP; Clauser SB; Castro K; Mitchell SA; Burke L; Trentacosti AM; Basch EM
Transl Behav Med; 2011 Mar; 1(1):110-22. PubMed ID: 24073038
[TBL] [Abstract][Full Text] [Related]
31. Use of the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to assess treatment tolerability in pulmonary arterial hypertension: qualitative patient research findings in current and former users of oral selexipag.
Davis S; Edwards T; Norcross L; Fehnel S; Beaudet A; Eckart M; Fastenau J
J Patient Rep Outcomes; 2023 Dec; 7(1):134. PubMed ID: 38108945
[TBL] [Abstract][Full Text] [Related]
32. Content Validity of Anatomic Site-Specific Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Sets for Assessment of Acute Symptomatic Toxicities in Radiation Oncology.
Sandler KA; Mitchell SA; Basch E; Raldow AC; Steinberg ML; Sharif J; Cook RR; Kupelian PA; McCloskey SA
Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):44-52. PubMed ID: 30102201
[TBL] [Abstract][Full Text] [Related]
33. The use of and adherence to CTCAE v3.0 in cancer clinical trial publications.
Zhang S; Chen Q; Wang Q
Oncotarget; 2016 Oct; 7(40):65577-65588. PubMed ID: 27564109
[TBL] [Abstract][Full Text] [Related]
34. Validity and Reliability of the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events.
Reeve BB; McFatrich M; Mack JW; Maurer SH; Jacobs SS; Freyer DR; Withycombe JS; Baker JN; Castellino SM; Lin L; Lucas NR; Hinds PS
J Natl Cancer Inst; 2020 Nov; 112(11):1143-1152. PubMed ID: 31999349
[TBL] [Abstract][Full Text] [Related]
35. Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors.
Knoerl R; Mazzola E; Mitchell SA; Hong F; Salehi E; McCleary N; Ligibel JA; Reyes K; Berry DL
J Patient Rep Outcomes; 2021 Sep; 5(1):101. PubMed ID: 34568984
[TBL] [Abstract][Full Text] [Related]
36. Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials.
Veitch ZW; Shepshelovich D; Gallagher C; Wang L; Abdul Razak AR; Spreafico A; Bedard PL; Siu LL; Minasian L; Hansen AR
J Natl Cancer Inst; 2021 Aug; 113(8):980-988. PubMed ID: 33616650
[TBL] [Abstract][Full Text] [Related]
37. Patient-reported Adverse Events During Neoadjuvant Therapy in a Phase 2 Borderline Resectable Pancreatic Cancer Clinical Trial (Alliance A021501).
Snyder RA; Dueck AC; Fruth B; Shi Q; Hubbard JM; Herman JM; O'Reilly EM; Katz MHG
Ann Surg; 2023 Oct; 278(4):598-608. PubMed ID: 37334719
[TBL] [Abstract][Full Text] [Related]
38. Selecting a PRO-CTCAE-based subset for patient-reported symptom monitoring in prostate cancer patients: a modified Delphi procedure.
Feldman E; Pos FJ; Smeenk RJ; van der Poel H; van Leeuwen P; de Feijter JM; Hulshof M; Budiharto T; Hermens R; de Ligt KM; Walraven I
ESMO Open; 2023 Feb; 8(1):100775. PubMed ID: 36652781
[TBL] [Abstract][Full Text] [Related]
39. Identifying Severe Adverse Event Clusters Using the National Cancer Institute's Common Terminology Criteria for Adverse Events.
Zhong X; Lim EA; Hershman DL; Moinpour CM; Unger J; Lee SM
J Oncol Pract; 2016 Mar; 12(3):e270-80, 245-6. PubMed ID: 26907453
[TBL] [Abstract][Full Text] [Related]
40. Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048.
Basch E; Dueck AC; Rogak LJ; Mitchell SA; Minasian LM; Denicoff AM; Wind JK; Shaw MC; Heon N; Shi Q; Ginos B; Nelson GD; Meyers JP; Chang GJ; Mamon HJ; Weiser MR; Kolevska T; Reeve BB; Bruner DW; Schrag D
J Clin Oncol; 2018 Sep; 36(31):JCO2018788620. PubMed ID: 30204536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]